Dupixent CTCL Lawsuit Attorney | Cutaneous T-Cell Lymphoma Claims

⏰ Strict Filing Deadlines Apply

With MDL No. 3180 active in New Jersey federal court, individual state Statutes of Limitations are strictly enforced. Missing a deadline permanently waives your right to pursue a claim against Sanofi and Regeneron.

The Primary Subtypes of Skin-Infiltrating T-Cell Malignancies

The active federal litigation is heavily centered on two main variants of CTCL, along with broader mature T-cell profiles:

Mycosis Fungoides (MF): Accounting for the majority of CTCL cases, mycosis fungoides is characterized by a slow but insidious progression.

It typically initiates as flat “patches” that evolve over months or years into thickened, indurated “plaques.”

If unchecked, the malignant T-lymphocytes eventually infiltrate the peripheral lymph nodes, bone marrow, and vital internal organs.

Sézary Syndrome (SS): is a far more aggressive, leukemic variant of CTCL. Sézary syndrome involves widespread intense, head-to-toe skin reddening and peeling accompanied by severe itchiness.

In Sézary syndrome, massive quantities of clonal, malignant T-cells (known as “Sézary cells”) circulate actively through the bloodstream and lymphatic pathways, resulting in a profoundly compromised immune state and significantly restricted clinical prognosis.

Other Non-Hodgkin & Mature T-Cell Lymphomas: Beyond CTCL, clinical studies have identified sudden onset or rapid advancement of broader T-cell and Natural Killer (NK) cell lymphomas in patients actively undergoing biologic treatment.

Why Are Lawsuits Being Filed Against the Makers of Dupixent?

Some patients prescribed Dupixent to treat eczema or other inflammatory skin conditions were later diagnosed with Cutaneous T-Cell Lymphoma CTCL. Because early symptoms of CTCL often resemble eczema, plaintiffs claim that the cancer diagnosis may have been delayed while patients continued treatment with the medication.

Dupixent is marketed as a breakthrough therapy, but emerging clinical evidence and adverse event reports reveal that Dupixent carries severe and potentially deadly risks that were omitted from or understated on the drug’s warning label:

1. Cutaneous T-Cell Lymphoma (CTCL): Allegations state that Dupixent alters interleukin signaling pathways (IL-4 and IL-13), suppressing initial skin symptoms while allowing underlying T-cell lymphoma to grow rapidly and go undetected.
2. Severe Ocular Surface Disorders (DAOSD): Including ulcerative keratitis, corneal scarring, and corneal perforation.

The Link Between Dupixent and Cutaneous T-Cell Lymphoma

Dupixent is a monoclonal antibody designed to block interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, suppressing the inflammatory response associated with atopic dermatitis. However, emerging medical literature and adverse event monitoring have raised critical concerns regarding T-cell malignancy proliferation.

1. Masking and Unmasking Early CTCL Symptoms

Early-stage Cutaneous T-Cell Lymphoma frequently presents as persistent, itchy red patches or plaques that closely mimic severe eczema. Lawsuits allege that Dupixent may suppress superficial skin inflammation while failing to treat the underlying malignant T-cells, causing a critical delay in proper biopsy and cancer diagnosis.

2. Alteration of T-Cell Signaling Pathways

Recent epidemiological studies and case series published in leading dermatology journals demonstrate an elevated relative risk of CTCL diagnoses among patients receiving dupilumab compared to non-users. Blocking specific interleukin pathways may inadvertently disrupt the body’s natural immune surveillance mechanisms against abnormal T-cell growth.

Allegations Against Dupixent Manufacturers (Sanofi & Regeneron)

Current legal actions allege that the makers of Dupixent:

• Failed to adequately test dupilumab’s long-term impacts on T-cell regulation and lymphoma risk prior to widespread commercial marketing.
• Failed to provide adequate warnings to prescribers and patients regarding the necessity of ruling out CTCL via skin biopsy prior to initiating therapy.
• Promoted the medication as safe for long-term chronic use without alerting the medical community to post-marketing reports of rapid CTCL progression.

The Core Legal Claim: Under product liability law, drug manufacturers are legally required to disclose all known or reasonably foreseeable risks associated with their medications.

Lawsuits allege Sanofi and Regeneron prioritized billions in sales over patient safety by failing to provide adequate warnings to prescribing physicians and consumers.

One of the critical issues raised in Dupixent litigation is the similarity between early-stage CTCL and eczema. CTCL and eczema skin conditions can appear similar; the symptoms of both conditions may include:

• Red, inflamed skin
• Persistent chronic itching
• Flaky and scaly skin patches
• Thickened and roughened skin
• Skin symptoms that improve and worsen over time

What is Dupixent?

Dupixent (dupilumab), manufactured by Sanofi and Regeneron Pharmaceuticals, is an injectable biologic prescribed to treat severe eczema (atopic dermatitis), asthma, chronic rhinosinusitis, eosinophilic esophagitis, and other medical conditions.

Dupixent was initially approved by the FDA in 2017 for moderate-to-severe atopic dermatitis, a common skin condition known as eczema.

Over the past few years, Dupixent has been approved to treat asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), prurigo nodularis, and several other inflammatory medical conditions.

How does Dupixent work?

Dupixent works by blocking specific immune pathways involved in inflammation and allergic responses. For many patients, Dupixent has improved symptoms when topical medications and other routine treatments fail. Dupixent is one of the world’s best-selling prescription drugs.

Scientific Data & Linked Medical Evidence

Many case reports and several clinical studies have found that the drug could “unmask” or worsen hidden lymphomas mistaken for eczema. This fact has heightened concerns that Dupixent not only failed to prevent worsening eczema symptoms but may have allowed hidden serious cancers to progress unchecked.

1. Cutaneous T-Cell Lymphoma (CTCL) & Mycosis Fungoides
   • The Mechanism: Dupixent inhibits IL-4 and IL-13 pathways. Researchers suggest this selective immunosuppression alters cutaneous immune surveillance, potentially accelerating malignant T-cell proliferation or masking early CTCL symptoms as simple eczema flare-ups.
   • Key Medical Findings:
     • FDA Safety Signal (March 2025): The FDA added Dupixent to its Potential Signals of Serious Risks list following hundreds of reported cases of T-cell lymphoma and mycosis fungoides.
     • The FDA’s Adverse Event Reporting System (FAERS) lists several hundred reports of lymphoma from Dupixent users, including many cases of cutaneous T-cell lymphoma, Sézary syndrome and other cancer subtypes.
     • According to medical experts, FDA reports are voluntary and unfortunately account for 1% to 10% of all reported injury cases, suggesting that the actual number of Dupixent CTCL cases is significantly higher.
     • Rapid Onset: Published case series indicate that many Dupixent-associated CTCL diagnoses occur within the first 12 months of starting therapy.

Significant Medical Studies

According to a study in the Journal of the American Academy of Dermatology, Dupixent users had a roughly four-times greater risk of developing cutaneous T-cell lymphoma (CTCL), a type of cancer. No increased risk was seen for other cancers. The study found that the cancer occurred more than one year after patients started taking the drug.

Another study in Dermatologic Therapy reported an increased risk of CTCL among Dupixent users. The risk was highest within the first year of treatment, and people over 60 were more susceptible.

In the journal Current Opinion in Immunology (2025), researchers concluded that while CTCL remains rare, evidence suggests that Dupixent may unmask or promote CTCL in certain patients.

A European study (March 2026) concluded that Dupilumab may unmask or exacerbate CTCL, particularly mycosis fungoides and Sézary syndrome. One year earlier, the European Respiratory Journal found that, while treatment with dupilumab for asthma resulted in significantly improved survival, it was associated with an increased risk of lymphoma, including mature T-cell and NK-cell lymphomas.

Although no single study establishes causation, plaintiffs argue that the growing body of evidence warranted stronger warnings and monitoring recommendations.

Recent Dupixent Lawsuits

In June 2026, William Douglas from Tennessee filed a lawsuit in New Jersey federal court, claimed that he developed mycosis fungoides after beginning Dupixent treatment in 2025. His lawsuit alleges that the manufacturers failed to update the medication’s warnings despite reports linking Dupixent to CTCL.

According to Douglas, the FDA issued a report in March 2025 warning of serious risks linking Dupixent to increasing rates of cancer. Douglas alleges that the manufacturers still refuse to correct the medication’s label warnings. Douglas’s doctors have advised him that he will probably need ongoing medical treatment and medical monitoring for the rest of his life.

Gabrielle Jackson, from Louisiana, filed a lawsuit in May 2026 in New Jersey federal court alleging that years of Dupixent treatment contributed to her development of CTCL. According to Ms. Jackson, she began using Dupixent for her eczema. She received Dupixent injections for five years before being diagnosed with CTCL in 2022. She reports undergoing radiation and chemotherapy following her diagnosis.

Anthony Baum from Illinois filed a lawsuit in April 2026 in Illinois federal court alleging he developed peripheral T-cell lymphoma (PTCL) within two months after beginning Dupixent treatment for severe eczema. According to Mr. Baum, he underwent chemotherapy, a stem-cell transplant, and developed additional complications. Baum claims that the companies withheld warnings for years despite case reports, epidemiological studies, and other scientific evidence linking Dupixent to T-cell lymphoma, and failed to conduct adequate testing or update the drug’s label even after cancer signals emerged.

In December 2025, Wanda Nalls filed a lawsuit in Georgia federal court, alleging she developed CTCL approximately three months after beginning Dupixent treatment for atopic dermatitis (eczema). According to Ms. Nalls, she has undergone radiation and chemotherapy treatments and faces ongoing medical care as a result of the disease.

Frequently Asked Questions

Q: Has the FDA recalled Dupixent due to cancer risks?

A: As of July 2026, the FDA has not issued a mandatory recall or added a black-box warning specifically for CTCL to the Dupixent prescribing label. However, regulatory authorities continue to review post-marketing safety reports, and individual lawsuits against manufacturers do not require an active FDA recall to proceed.

Q: What compensation can be recovered in a Dupixent lawsuit?

A: Victims of delayed cancer diagnosis or accelerated CTCL may seek compensation for past and future medical expenses, specialized oncology care, lost wages, loss of earning capacity, pain and suffering, emotional distress, and, in tragic cases, wrongful death damages.

Q: How much does it cost to hire a Dupixent lawyer?

A: We handle all product liability cases on a contingency fee basis. You pay nothing upfront, and we only receive a fee if we successfully win a settlement or jury verdict on your behalf.

Q: What is the Statute of Limitations for filing a Dupixent lawsuit?

A: Time limits vary by state and usually start running from the date of your diagnosis, not when you first took the medication. Because statutes of limitations can be as short as 1 to 2 years depending on your state, it is critical to contact an attorney promptly.

Q: Is there a Dupixent settlement yet?

A: Litigation is currently in the discovery and pretrial stages within federal MDL No. 3180. No global settlement has been announced yet, but individual claims are being actively prepared.

Q: What types of cancers is Dupixent associated with?

Federal lawsuits and medical literature focus heavily on a range of skin-infiltrating malignancies, which you can review in detail in our comprehensive breakdown of the Primary Dupixent T-Cell Cancer Subtypes above.

Q: Can Dupixent cause or accelerate Cutaneous T-Cell Lymphoma?

A: Yes, medical studies and emerging data indicate that Dupixent can accelerate, unmask, or increase the risk of Cutaneous T-Cell Lymphoma (CTCL). The relationship between Dupixent and CTCL—a rare form of non-Hodgkin lymphoma that affects the skin—is complex.

Q: Why is early-stage CTCL often misdiagnosed as severe eczema?

A: Because the symptoms look identical, it underscores why a prior skin biopsy is legally significant to the failure-to-warn claim. 

The following types of cancer have been discussed in medical literature and legal claims:

Cutaneous T-Cell Lymphoma: This is the most commonly reported cancer in Dupixent users, often initially mistaken for eczema before a proper diagnosis.
Sézary Syndrome: An advanced and aggressive form of CTCL that can involve the blood and lymph nodes.
Other Non-Hodgkin Lymphomas: Some patients have reported broader lymphoma diagnoses beyond CTCL, raising questions about Dupixent’s effect on abnormal white blood cells.
NK Cell Lymphomas: Rare cancers of natural killer cells, occasionally identified in patients with Dupixent use.
Skin Cancers Misdiagnosed as Dermatitis: Early signs of lymphoma may resemble basal cell or squamous cell carcinoma, leading to diagnostic confusion and delayed treatment.

Serving Injured Dupixent Patients Throughout Texas
As a specialized product liability firm with physical offices in Dallas and Fort Worth, the Dr. Shezad Malik Law Firm protects the rights of drug safety victims statewide. We actively review Dupixent lymphoma oncology files for clients throughout the DFW Metroplex (including Arlington, Plano, Irving, Frisco, and McKinney), as well as major Texas regions such as Houston, Austin, San Antonio, and El Paso. If you were prescribed this medication by a dermatologist, immunologist, or pulmonologist at any major Texas medical hub and subsequently developed a skin-infiltrating T-cell malignancy, our local legal team is equipped to fight for your comprehensive financial recovery.